MICYRN Secures $20 Million Grant from CIHR for a Pediatric Rare Disease Clinical Trials and Treatment Network

The NMD4C are excited to share MICYRN‘s success in securing a $20 million grant from CIHR Institute of Genetics to support the development and execution of RareKids-CAN: Pediatric Rare Disease Clinical Trials and Treatment Network. Under the leadership of MICYRN’s Scientific Director, and Nominated Principal Applicant, Dr. Thierry Lacaze-Masmonteil, RareKids-CAN is a transformative initiative set to revolutionize the landscape of rare disease research and treatment for children and their families in Canada and beyond.  

At the core of RareKids-CAN is a coalition of diverse national and international experts including patient/family partners and patient organizations pooling their collective knowledge and experience in the pediatric rare disease community. Leveraging the strengths of MICYRN and its 17 maternal/child health research institutions, aimed at streamlining complex, pediatric, multi-center, multi-jurisdictional clinical trials, RareKids-CAN is primed for swift and effective operationalization. 

RareKids-CAN aims to establish a robust platform in Canada to support pediatric rare disease clinical trials, providing essential infrastructure and resources. It seeks to enhance capacity through comprehensive training and mentorship opportunities, attract international trials and investments, foster inclusivity, and improve accessibility. The network prioritizes data collection and analysis to inform decision-making, while also supporting increased submissions for Health Canada authorization, ensuring timely access to innovative therapies for those impacted by rare diseases.

 

NMD4C Investigators involved with RareKids-CAN network grant

The NMD4C is excited to support this initative – we were pleased to share a letter of support for the grant application, and celebrate the many NMD4C investigators who are a part of the RareKids-CAN network: 

 

For more information, please visit MICYRN’s website.

Pediatric Rare Disease Clinical Trials and Treatment Network - RareKids-CAN

Read next...

Text reading NMD4C joins bluesky - We're now active on Bluesky! We invite you to follow us at @nmd4c.ca to stay updated on news from our Canadian neuromuscular network. NMD4C and bluesky logo, with an image of the NMD4C bluesky feed.

You Can Now Find NMD4C on Bluesky

We’re moving to Bluesky! The NMD4C will now share updates on Bluesky instead of X. Please consider following us at @nmd4c.ca to stay connected! 

CIHR Funds Interdisciplinary Project to Study SBMA in Indigenous Peoples of the Prairie Provinces The NMD4C is excited to share that network investigators Drs. Gerald Pfeffer, Alexandra King, Kerri Schellenberg, Toshifumi Yokota and Malcolm King have been awarded funding from the CIHR for an Interdisciplinary Spinal-bulbar muscular atrophy study in Indigenous peoples of the prairie provinces

CIHR Funds Interdisciplinary Project to Study SBMA in Indigenous Peoples of the Prairie Provinces

The NMD4C is excited to share that network investigators have been awarded funding from the CIHR for an Interdisciplinary Spinal-bulbar muscular atrophy study in Indigenous peoples of the prairie provinces, addressing the community needs, and developing clinical knowledge and therapies.

2025 NMD4C early career award winners profile pictures, text reading Congratulations Early Career Award Winners

NMD4C Presents the 2025 Early Career Award Recipients

We are excited to announce the recipients of the 2025 NMD4C Early Career Awards! This is the third year of our annual award program, celebrating excellence and contribution to the neuromuscular field from early career investigators across both clinical and basic science streams.

Muscular Dystrophy Canada is thrilled to launch an innovative initiative designed to tackle the diagnostic hurdles experienced by individuals with myotonic dystrophy.

Muscular Dystrophy Canada Launches Initiative to Improve Genetic Testing Access for Myotonic Dystrophy

Muscular Dystrophy Canada is thrilled to launch an innovative initiative designed to tackle the diagnostic hurdles experienced by individuals with myotonic dystrophy.

LEARNMD content update - February 2025

New Content Available in LEARNMD

LEARNMD is the NMD4C’s online educational platform, offering talks and sessions on a wide range of neuromuscular topics presented by leading clinical and scientific experts worldwide. We’re excited to share what’s new on LEARNMD in February 2025!

RQAS logo

Quebec Network Réseau Québécoise de l’Amyotrophie Spinale Joins NMD4C as Community of Practice Sub-Group

We are thrilled to announce that the RQAS, a network uniting rehabilitation clinicians across Quebec to advance the care of people with Spinal Muscular Atrophy has officially become a sub-group Community of Practice of the NMD4C